677 Views | 288 Downloads
Corresponding Author: Tanya N. Turan, MD MS, MUSC Stroke Program, 19 Hagood Avenue, Suite 501, Harborview Office Tower, Charleston, SC 29425, phone: 843-792-3020, fax: 843-792-2484, turan@musc.edu
Acknowledgments: The PACE self-assessment forms for smoking cessation and physical activity were provided by the San Diego Center for Health Interventions, LLC.
Vendors: INTERxVENT provides the lifestyle modification program to the study at a discounted rate.
The Veterans Affairs Cooperative Studies Program Clinical Research Pharmacy Coordinating Center (Albuquerque, NM) handled the procurement, labeling, distribution, and inventory management of the study devices and rosuvastatin.
Walgreens pharmacies provide study medications except rosuvastatin to study patients at a discounted price (paid for by the study).
Disclosures: Drs. Turan, Derdeyn, Fiorella, Janis, and Chimowitz, and Michael Lynn MS, and Bethany Lane RN, MSN serve on the Executive Committee of the SAMMPRIS trial, which is funded by the National Institute of Neurological Disorders and Stroke (NINDS) (grant number: U01 NS058728).
All except Dr. Janis have received salary support from the SAMMPRIS grant.
Dr. Turan is currently supported by a NINDS K23 award (K23 NS069668).
Dr. Janis is the NINDS Program Officer for the trial.
Drs. Egan, Le, Lopes-Virella, Hermayer, Benavente, White, and Brown serve on the SAMMPRIS Risk Factor Committee and were reimbursed from the SAMMPRIS grant for these efforts.
Azhar Nizam MS serves at the Statistical Coordinating Center and receives salary support from the SAMMPRIS grant.
Michelle Caskey, Meghan Steiner, Nicole Vilardo and Andrew Stufflebean served in support roles for the Risk Factor Committee and received salary support from the SAMMPRIS grant for these efforts.
None of the authors have any financial relationship with the INTERxVENT Lifestyle Program.
See publication for full list of additional support.
The SAMMPRIS trial was funded by a research grant (U01 NS058728) from the United States Public Health Service National Institute of Neurological Disorders and Stroke (NINDS).
In addition, Dr. Tanya Turan’s NIH-funded K23 grant award (1 K23 NS069668-01A1), provided support for her time and effort as the Director of Risk Factor Management.
Corporate Support: Stryker Neurovascular (formerly Boston Scientific Neurovascular) provided study devices and supplemental funding for third party device distribution, site monitoring and study auditing.
This research is also supported by the Investigator-Sponsored Study Program of AstraZeneca that donates rosuvastatin (Crestor) to study patients.
© 2012 American Heart Association, Inc.